IDEXX Laboratories Inc (IDXX)

NASDAQ
Currency in USD
459.78
-0.78(-0.17%)
Closed
After Hours
459.60-0.18(-0.04%)
IDXX Scorecard
Full Analysis
Management has been aggressively buying back shares
Fair Value
Day's Range
457.35468.80
52 wk Range
398.50583.39
Key Statistics
Edit
Prev. Close
460.56
Open
465
Day's Range
457.35-468.8
52 wk Range
398.5-583.39
Volume
624.59K
Average Volume (3m)
652.07K
1-Year Change
-19.84%
Book Value / Share
19.48
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
IDXX Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
495.85
Upside
+7.85%
Members' Sentiments
Bearish
Bullish
ProTips
7 analysts have revised their earnings downwards for the upcoming period
Show more

IDEXX Laboratories Inc Company Profile

IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory diagnostic instruments, and services for biomedical research community. In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits. Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups. Additionally, the company offers human medical point-of-care products and laboratory diagnostics services. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

IDEXX Laboratories Inc SWOT Analysis


Market Leadership
Explore IDEXX's dominance in veterinary diagnostics, balancing declining visits with increased utilization and innovative product launches
Financial Resilience
Despite market headwinds, IDEXX maintains robust profitability with a 60.7% gross margin and 7.2% revenue growth, showcasing its financial strength
Growth Projections
Analysts forecast sustainable double-digit top-line growth for IDEXX, with price targets ranging from $481 to $630, reflecting optimistic long-term outlook
Strategic Innovation
Delve into IDEXX's product development strategy, including the inVue Dx Analyzer and IDXX Cancer Dx, driving competitive advantage in a evolving market
Read full SWOT analysis

IDEXX Laboratories Inc Earnings Call Summary for Q3/2024

  • Q3 organic revenue up 6%, EPS rose 11% YoY to $2.80; full-year guidance revised to 5.3%-6% growth
  • CAG diagnostics recurring revenue growth adjusted to 5.8%-6.4%; total 2024 revenue forecast $3.865B-$3.890B
  • Strong gross margins at 61.1%; customer retention over 97%; growth in premium instrument installed base
  • Q4 organic growth projected at 3%; recurring revenue growth 3.5%-4%; long-term pet care spending outlook positive
  • New product launches, including IDEXX inVue Dx Cellular Analyzer, expected to drive future growth
Last Updated: 02/11/2024, 12:22 am
Read Full Transcript

Compare IDXX to Peers and Sector

Metrics to compare
IDXX
Peers
Sector
Relationship
P/E Ratio
42.4x7.1x−0.6x
PEG Ratio
6.990.220.00
Price/Book
23.6x2.2x2.6x
Price / LTM Sales
9.7x3.2x3.1x
Upside (Analyst Target)
13.1%43.3%52.1%
Fair Value Upside
Unlock−0.7%8.2%Unlock

Analyst Ratings

7 Buy
6 Hold
1 Sell
Ratings:
14 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 495.85
(+7.85% Upside)

Earnings

Latest Release
Feb 03, 2025
EPS / Forecast
2.62 / 2.39
Revenue / Forecast
954.28M / 933.38M
EPS Revisions
Last 90 days

People Also Watch

58.21
CPRT
-1.66%
171.43
ZTS
-1.54%
679.24
AXON
+0.27%
242.08
UNP
-0.59%
192.02
CDW
-3.92%

FAQ

What Is the IDEXX Labs (IDXX) Stock Price Today?

The IDEXX Labs stock price today is 459.78

What Stock Exchange Does IDEXX Labs Trade On?

IDEXX Labs is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for IDEXX Labs?

The stock symbol for IDEXX Labs is "IDXX."

What Is the IDEXX Labs Market Cap?

As of today, IDEXX Labs market cap is 37.65B.

What is IDEXX Labs Earnings Per Share?

The IDEXX Labs EPS is 10.77.

What Is the Next IDEXX Labs Earnings Date?

IDEXX Labs will release its next earnings report on 29 Apr 2025.

From a Technical Analysis Perspective, Is IDXX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.